Human interferon-alpha increases the cytotoxic effect of CD56⁺cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines

References

• Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605–15.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.
   PubMed Web of Science ®Google Scholar
• Uderzo C, Conter V, Dini G, Locatelli F, Miniero R, Tamaro P. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Haematologica. 2001;86:1–7.
   PubMed Web of Science ®Google Scholar
• National Marrow Donor Program. Trends in Allogeneic Transplants. Available from: http://marrow.org/Physicians/Unrelated_Search_and_Transplant/Trends_in_Allo_ Transplants.aspx. (accessed May, 2012).
   Google Scholar
• Gluckman E, Rocha V. Indications and results of cord blood transplant in children with leukemia. Bone Marrow Transplant. 2008;41(Suppl 2):S80–2.
   Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–83.
   PubMed Web of Science ®Google Scholar
• Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, . Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26:511–6.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, . Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–50.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee JH, Kim S, Lee YS, Seol M, Ryu SG, . Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant. 2005;36:163–9.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, . Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673–9.
   PubMed Web of Science ®Google Scholar
• Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, . Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 2006;38:621–7.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+NK− T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001;7:532–42.
   PubMed Web of Science ®Google Scholar
• Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101:640–8.
   PubMed Web of Science ®Google Scholar
• Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, . Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA. 1999;96:12044–9.
   PubMed Web of Science ®Google Scholar
• Wongkajornsilp A, Somchitprasert T, Butraporn R, Wamanuttajinda V, Kasetsinsombat K, Huabprasert S, . Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice. Cancer Invest. 2009;27:140–8.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, . Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine- induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008;20:841–8.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, . In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112:2563–74.
   PubMed Web of Science ®Google Scholar
• Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8( ) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923–31.
   PubMed Web of Science ®Google Scholar
• Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009;27:130–9.
   PubMed Web of Science ®Google Scholar
• Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, . Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92:952–9.
   PubMed Web of Science ®Google Scholar
• Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, . The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. >Bone Marrow Transplant. 2012;47:957–66.
   Google Scholar
• Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002;116:78–86.
   PubMed Web of Science ®Google Scholar
• Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, . Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol. 2006;34:1219–29.
   PubMed Web of Science ®Google Scholar
• Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, . Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007;178:7540–9.
   PubMed Web of Science ®Google Scholar
• Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine. 2003;24:81–90.
   PubMed Web of Science ®Google Scholar
• Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, . Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+T cell responses against human tumor antigens. J Immunol. 2004;172:5363–70.
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, . Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, . Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018–23.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Kabisch A, Lubbert M, . Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL). Leukemia. 2003;17:1919–24.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Martinelli G, Isidori A, Malagola M, Rondoni M, Paolini S, . Long-term molecular complete remission with IFN-alpha in Ph adult acute lymphoid leukemia patients. Leukemia. 2008;22:1617–8.
   PubMed Web of Science ®Google Scholar
• Gregoire-Gauthier J, Durrieu L, Duval A, Fontaine F, Dieng MM, Bourgey M, . Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/gammac- mouse model. Bone Marrow Transplant. 2012;47:439–50.
   Google Scholar
• Gregoire-Gauthier J, Selleri S, Fontaine F, Dieng MM, Patey N, Despars G, . Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model. Stem Cells Dev. 2012;21:1616–26.
   PubMedGoogle Scholar
• Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994;87:453–8.
   PubMed Web of Science ®Google Scholar
• Liang S, Wei H, Sun R, Tian Z. IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine. 2003;23:190–9.
   PubMed Web of Science ®Google Scholar
• Dalle JH, Duval M, Moghrabi A, Wagner E, Vachon MF, Barrette S, . Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant. 2004;33:605–11.
   PubMed Web of Science ®Google Scholar
• Laurin D, Marin V, Biagi E, Pizzitola I, Agostoni V, Gallot G, . Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells. J Biomed Biotechnol. 2010; DOI: 10.1155/2010/234540.
   PubMedGoogle Scholar
• Erhardt M, Schmidt-Wolf IG, Sievers E, Frank S, Strehl J, von Lilienfeld-Toal M, . Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells. Arch Immunol Ther Exp (Warsz). 2006;54:403–9.
   PubMed Web of Science ®Google Scholar
• Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, . Type I-IFNs control GVHD and GVL responses after transplantation. Blood. 2011;118:3399–409.
   PubMedGoogle Scholar
• Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, . Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol. 2001;31:3138–46.
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med. 1999;189:1451–60.
   PubMed Web of Science ®Google Scholar
• Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, . The cytotoxic potential of interleukin- 15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2012;14:91–103.
   PubMed Web of Science ®Google Scholar
• Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, . Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol. 2007;7:1793–801.
   PubMed Web of Science ®Google Scholar
• Petvises S, Pakakasama S, Wongkajornsilp A, Sirireung S, Panthangkool W, Hongeng S. Ex vivo generation of cytokine-induced killer cells (CD3+CD56+) from post-stem cell transplant pediatric patients against autologous Epstein– Barr virus-transformed lymphoblastoid cell lines. Pediatr Transplant. 2007;11:511–7.
   PubMedGoogle Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+ CD56+cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–96.
   PubMed Web of Science ®Google Scholar
• Kim HM, Lim J, Park SK, Kang JS, Lee K, Lee CW, . Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol. 2007;7:1802–7.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lim J, Kang JS, Kim HM, Lee HK, Ryu HS, . Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res. 2010;33:1789–95.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther. 2009;9:831–40.
   PubMed Web of Science ®Google Scholar
• Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010;DOI:10.1155/2010/435745.
   PubMedGoogle Scholar
• Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, . Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol. 2011;11:449–56.
   PubMed Web of Science ®Google Scholar
• Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Mico C, . Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant. 2010;16:1603–7.
   PubMed Web of Science ®Google Scholar
• Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, . Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation. 2009;87:1654–8.
   Google Scholar
• Cooper N, Rao K, Goulden N, Amrolia P, Veys P. Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias. Br J Haematol. 2012;156:550–2.
   PubMedGoogle Scholar